RDA Financial Network Sells 2,375 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

RDA Financial Network decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 32.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,017 shares of the pharmaceutical company's stock after selling 2,375 shares during the quarter. RDA Financial Network's holdings in Vertex Pharmaceuticals were worth $2,020,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in VRTX. Axxcess Wealth Management LLC grew its stake in Vertex Pharmaceuticals by 9.7% during the second quarter. Axxcess Wealth Management LLC now owns 2,445 shares of the pharmaceutical company's stock valued at $1,146,000 after acquiring an additional 217 shares in the last quarter. Bradley Foster & Sargent Inc. CT grew its position in shares of Vertex Pharmaceuticals by 2.2% during the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 1,896 shares of the pharmaceutical company's stock valued at $889,000 after purchasing an additional 40 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Vertex Pharmaceuticals by 23.2% in the second quarter. Mercer Global Advisors Inc. ADV now owns 16,503 shares of the pharmaceutical company's stock worth $7,697,000 after buying an additional 3,106 shares in the last quarter. Blair William & Co. IL boosted its stake in Vertex Pharmaceuticals by 25.7% during the second quarter. Blair William & Co. IL now owns 89,108 shares of the pharmaceutical company's stock valued at $41,767,000 after buying an additional 18,197 shares during the period. Finally, Waterloo Capital L.P. purchased a new position in Vertex Pharmaceuticals during the second quarter worth about $352,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Trading Up 1.2 %

Shares of VRTX traded up $5.04 during mid-day trading on Friday, hitting $422.00. 1,771,827 shares of the company's stock traded hands, compared to its average volume of 1,811,179. The business's 50-day moving average price is $442.83 and its 200-day moving average price is $466.48. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The firm has a market capitalization of $108.68 billion, a P/E ratio of -212.06, a PEG ratio of 2.11 and a beta of 0.40. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same period in the prior year, the business earned $3.67 EPS. The company's revenue for the quarter was up 11.6% on a year-over-year basis. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on VRTX shares. Royal Bank of Canada lifted their price target on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a "sector perform" rating in a research report on Tuesday, November 5th. William Blair reiterated an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Monday, January 13th. Truist Financial decreased their price target on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a "buy" rating on the stock in a report on Monday, December 23rd. JPMorgan Chase & Co. dropped their price objective on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating for the company in a report on Monday, December 23rd. Finally, Bank of America reduced their target price on Vertex Pharmaceuticals from $545.00 to $522.00 and set a "buy" rating on the stock in a research note on Thursday, December 19th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $490.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.